All In Biotech

Drug Trial Radar · NCT05291234

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Aug 15, 2022

Primary completion

Nov 19, 2025

Study completion Nov 19, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed. ABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are "double-blind," which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world. Participants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires.

Conditions

  • Alzheimer's Disease (AD)

Interventions

  • ABBV-916Drug

    Intravenous administration

  • PlaceboDrug

    Intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 160 weeks
  2. Stage A: Maximum Observed Serum Concentration (Cmax) for Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
  3. Stage A: Time to Cmax (Tmax) for Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
  4. Stage A: Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-916Time frame: Up to approximately 24 weeks
  5. Stage A: Terminal Phase Elimination Half-Life (t1/2) of ABBV-916Time frame: Up to approximately 24 weeks
  6. Stage A: Trough Serum Concentration (Ctrough) of ABBV-916 at the End of a Dosing IntervalTime frame: Up to approximately 24 weeks
  7. Stage A: Area Under the Concentration-Time Curve (AUC) of ABBV-916Time frame: Up to approximately 24 weeks
  8. Stage A: Cerebrospinal Fluid (CSF) Concentration as a Measure of ABBV-916 Crossing the Blood Brain BarrierTime frame: Up to approximately 24 weeks
  9. Stage A: Percentage of Participants With Antidrug Antibodies (ADA) as a Measure of Immunogenicity Following Multiple Ascending Dose of ABBV-916Time frame: Up to approximately 24 weeks
  10. Stage B: Change in Brain Amyloid Plaque Deposition (Amyloid Centiloid Value)Time frame: Baseline (Week 0) through Week 24

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Tucson Neuroscience Research /ID# 244957

    Tucson, Arizona

  • Irvine Clinical Research /ID# 239469

    Irvine, California

  • Artemis Institute for Clinical Research - San Diego /ID# 244508

    San Diego, California

  • Pacific Research Network, Inc. /ID# 244083

    San Diego, California

  • Syrentis Clinical Research /ID# 239682

    Santa Ana, California

  • Aventura Neurological Associates /ID# 243892

    Aventura, Florida

  • Charter Research - Lady Lake /ID# 244657

    Lady Lake, Florida

  • JEM Research Institute /ID# 239122

    Lake Worth, Florida

  • ClinCloud - Maitland /ID# 244507

    Maitland, Florida

  • ClinCloud LLC - Viera/Melbourne /ID# 240635

    Melbourne, Florida

  • Merritt Island Medical Research /ID# 239495

    Merritt Island, Florida

  • Optimus U /ID# 245868

    Miami, Florida

  • Finlay Medical Research /ID# 245996

    Miami, Florida

  • Allied Biomedical Res Inst Inc /ID# 244823

    Miami, Florida

  • Renstar Medical Research /ID# 240153

    Ocala, Florida

  • K2 Medical Research - Ocoee /ID# 246849

    Ocoee, Florida

  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 243919

    Orlando, Florida

  • Charter Research - Winter Park /ID# 244778

    Orlando, Florida

  • Headlands Research - Orlando /ID# 239119

    Orlando, Florida

  • Neurology Associates Ormond Beach /ID# 245527

    Ormond Beach, Florida

  • IMIC Inc. Medical Research /ID# 245900

    Palmetto Bay, Florida

  • Alzheimer's Research and Treatment Center - Stuart /ID# 245477

    Stuart, Florida

  • Alzheimer's Research and Treatment Center - Wellington /ID# 245201

    Wellington, Florida

  • Premiere Research Institute - Palm Beach /ID# 240108

    West Palm Beach, Florida

  • Clinical Site Partners (CSP) - Orlando /ID# 245127

    Winter Park, Florida

  • Conquest Research /ID# 243916

    Winter Park, Florida

  • Columbus Memory Center /ID# 245054

    Columbus, Georgia

  • QUEST Research Institute /ID# 239459

    Farmington Hills, Michigan

  • Advanced Memory Research Institute of NJ /ID# 239533

    Toms River, New Jersey

  • Keystone Clinical Studies LLC /ID# 239973

    Plymouth Meeting, Pennsylvania

  • Clinical Trials of Texas, Inc /ID# 244917

    San Antonio, Texas

  • Re:Cognition Health - Fairfax VA /ID# 239501

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.